CGEN
NASDAQ
$2.34
Compugen Ltd (CGEN)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $4.60 (+96.58%)
Market Cap
$223M
Revenue 5Y CAGR
+57.53%
Profit Margin
48.6%
P/E Ratio
6.31
Price Chart
Valuation
Market Cap$223M
P/E6.31
Forward P/E12.36
PEG1.29
P/S2.99
P/B2.29
Profitability
Total Revenue (TTM)$73M
Gross Profit (TTM)$64M
EBITDA$32M
Profit Margin48.6%
Operating Margin43.1%
EPS$0.37
Financial Health
Free Cash Flow Yield14.04%
Growth & Risk
Revenue 5Y CAGR+57.53%
Beta (5Y)1.44
Sharpe Ratio0.84